Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (10): 1168-1176.doi: 10.12092/j.issn.1009-2501.2023.10.011

Previous Articles     Next Articles

Research progress on the antitumor activity of costunolide

LIU Dan1, LIU Ming2, JIN Liangyou3, PAN Juan1, XIN Haoru1, LIU Mengyuan1, LI Xin1, ZHENG Kun1, FENG Xiaoling1   

  1. 1Chongqing Three Gorges Medical College Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Wanzhou 404120, Chongqing, China; 2Chongqing College of Mobile Communication, Qijiang 404120, Chongqing, China; 3Chongqing Three Gorges University, Wanzhou 404120, Chongqing, China
  • Received:2023-03-31 Revised:2023-07-07 Online:2023-10-26 Published:2023-10-26

Abstract:

In recent years, the research on the anti-tumor effect of traditional Chinese medicine has been increasing year by year. Both the effective extracted ingredients of Chinese medicine and its compound preparations have significant efficacy and advantages in tumor treatment. Costunolide, the active ingredient of Aucklandia lappa (a traditional Chinese medicine), is a natural sesquiterpene lactone, which has a variety of pharmacological effects, such as anti-oxidation, anti-inflammation, hypoglycemic effect, anti-microbial effect etc. In recent years, more and more experimental studies in vivo and in vitro have shown that this component has anti-tumor activity, which can inhibit the growth of breast cancer, gastric cancer, melanoma cancer, prostate cancer, leukemia, liver cancer, lung cancer, ovarian cancer, esophageal cancer, colorectal cancer, osteosarcoma and other tumors. Its anti-tumor mechanism mainly lies in the regulation of PI3K/AKT/mTOR, AKT-MDM 2-p53, ROS-AKT/GSK-3β, Bcr/Abl, Stat5 and other signaling pathways, which affects reactive oxygen species, apoptosis-related proteins, autophagy-related proteins, and cyclin, and thus induces apoptosis, causes autophagy and arrests cell cycle in G2/M phase, G1 phase, and S phase. In addition, the combination of costunolide with imatinib and doxorubicin can attenuate toxicity and enhance anti-tumor effect, and also reverse tumor drug resistance. By consulting and sorting out the relevant research literature at home and abroad, the author summarized the research progress of costunolide on the antitumor effect and mechanism, the combined drug use and the reversal of tumor drug resistance in order to provide theoretical basis for the development and utilization of new drugs of this ingredient.

Key words: costunolide, tumor, mechanism, research progress, combination

CLC Number: